Trial · NCT00514046
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximum Tolerated Dose (MTD) | All Participants | 100 | mg/m^2/day | ||
| Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR) | All Participants | 59 | 95% Confidence Interval 33 to 82 | percentage of participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | <50% decrease/<50% increase | 1 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib 100 mg/m^2 | <50% decrease/<50% increase | 1 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | <50% decrease/<50% increase | 1 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | <50% decrease/<50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib 100 mg/m^2 | >50% increase | 1 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | >50% increase | 0 | Participants | |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | >50% increase | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00514046/results